At JPM26, Gilead showcased strong momentum as Yeztugo’s impressive sales and positive HIV treatment outlook boosted investor sentiment, capturing the optimistic mood at the biotech conference.
Browsing: Gilead
Drugmaker Gilead Sciences announced an $11 billion investment to expand its U.S. manufacturing capabilities, aiming to boost production capacity and job growth, the San Francisco Business Times reports.